![Business Of Biotech podcast](/assets/images/square.png)
We love to hear from our listeners. Send us a message.
Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put on a precision medicine clinic, so to speak. What’s more, Radiopharmaceuticals create a unique business opportunity given the closely-related and necessary companion diagnostic arena. On today’s episode of the Business of Biotech, recorded in San Francisco, we sit down with Dr. Mark Hoppin, CEO of Ratio Therapeutics, a company that’s well-positioned in the space with a fresh Series B and the foundation of a tunable radiotherapeutic that Dr. Hoppin says addresses the delivery, safety and efficacy challenges long associated with radiopharmaceuticals in the treatment of solid cancers. We also discuss how this mathemetician-turned biotech CEO has navigated the leadership of boards, employees, and investors on his journey.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/
Altri episodi di "Business Of Biotech"
Non perdere nemmeno un episodio di “Business Of Biotech”. Iscriviti all'app gratuita GetPodcast.